HPV DNA integration site as proof of the origin of ovarian metastasis from endocervical adenocarcinoma: three case reports.


Journal

BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800

Informations de publication

Date de publication:
23 Apr 2019
Historique:
received: 03 12 2018
accepted: 05 04 2019
entrez: 25 4 2019
pubmed: 25 4 2019
medline: 6 8 2019
Statut: epublish

Résumé

Most endocervical adenocarcinomas are human papillomavirus (HPV)-related cancers associated with p16 immunostaining. Ovarian metastasis from cervical cancer is a rare phenomenon, the mechanism of dissemination remains unclear. The diagnosis of metastasis may be difficult to establish when the ovarian neoplasm presents features consistent with primary tumor. Immunohistochemical expression of p16 in ovarian tumors can guide the diagnosis of metastasis from HPV-related cervical cancer, but p16 positivity is nonspecific. Identical HPV genotype in the paired endocervical and ovarian tumors is a better marker for cervical origin, which may also be confirmed by identical HPV integration site. Two women presented with HPV18 cervical adenocarcinoma. No signs of disease were visible on MRI after treatment. After several years of follow-up, mucinous ovarian tumors were discovered in both patients. Molecular analyses showed that the ovarian lesions were HPV18-positive; indicating a primary cervical origin. A third woman was diagnosed with grade 1 ovarian endometrioid carcinoma with no peritoneal carcinomatosis. Final histological examination and HPV genotyping revealed HPV18-related in situ endometrioid adenocarcinoma in the endocervix and HPV18-related invasive endometrioid adenocarcinoma in the endometrium and both ovaries. Additional molecular analyses performed in two patients identified the same HPV integration sites in both the ovarian and cervical tumors, confirming that the ovarian mass was a metastasis from the cervical adenocarcinoma. We report three new cases of ovarian neoplasia in which the diagnosis of metastasis from cervical cancer was supported by the same HPV genotype and the same integration site in the paired cervical and ovarian tumors. To our knowledge, this is the first report of molecular evidence of the cervical origin of an ovarian metastasis. HPV screening should be performed in ovarian tumors for all patients with history of cervical neoplasia.

Sections du résumé

BACKGROUND BACKGROUND
Most endocervical adenocarcinomas are human papillomavirus (HPV)-related cancers associated with p16 immunostaining. Ovarian metastasis from cervical cancer is a rare phenomenon, the mechanism of dissemination remains unclear. The diagnosis of metastasis may be difficult to establish when the ovarian neoplasm presents features consistent with primary tumor. Immunohistochemical expression of p16 in ovarian tumors can guide the diagnosis of metastasis from HPV-related cervical cancer, but p16 positivity is nonspecific. Identical HPV genotype in the paired endocervical and ovarian tumors is a better marker for cervical origin, which may also be confirmed by identical HPV integration site.
CASE PRESENTATION METHODS
Two women presented with HPV18 cervical adenocarcinoma. No signs of disease were visible on MRI after treatment. After several years of follow-up, mucinous ovarian tumors were discovered in both patients. Molecular analyses showed that the ovarian lesions were HPV18-positive; indicating a primary cervical origin. A third woman was diagnosed with grade 1 ovarian endometrioid carcinoma with no peritoneal carcinomatosis. Final histological examination and HPV genotyping revealed HPV18-related in situ endometrioid adenocarcinoma in the endocervix and HPV18-related invasive endometrioid adenocarcinoma in the endometrium and both ovaries. Additional molecular analyses performed in two patients identified the same HPV integration sites in both the ovarian and cervical tumors, confirming that the ovarian mass was a metastasis from the cervical adenocarcinoma.
CONCLUSION CONCLUSIONS
We report three new cases of ovarian neoplasia in which the diagnosis of metastasis from cervical cancer was supported by the same HPV genotype and the same integration site in the paired cervical and ovarian tumors. To our knowledge, this is the first report of molecular evidence of the cervical origin of an ovarian metastasis. HPV screening should be performed in ovarian tumors for all patients with history of cervical neoplasia.

Identifiants

pubmed: 31014281
doi: 10.1186/s12885-019-5582-8
pii: 10.1186/s12885-019-5582-8
pmc: PMC6480742
doi:

Substances chimiques

DNA, Viral 0

Types de publication

Case Reports Journal Article

Langues

eng

Pagination

375

Références

Int J Cancer. 2001 Apr 1;92(1):9-17
pubmed: 11279600
J Pathol. 2003 Dec;201(4):535-43
pubmed: 14648656
Gynecol Oncol. 2006 May;101(2):234-7
pubmed: 16300819
Am J Surg Pathol. 2005 Dec;29(12):1686-7; author reply 1687-9
pubmed: 16327448
Int J Gynecol Cancer. 2006 Jan-Feb;16(1):347-53
pubmed: 16445657
Am J Surg Pathol. 2007 May;31(5):653-63
pubmed: 17460447
Int J Gynecol Pathol. 2010 Jan;29(1):88-92
pubmed: 19952931
J Pathol. 2010 Jul;221(3):320-30
pubmed: 20527025
Lancet Oncol. 2010 Nov;11(11):1048-56
pubmed: 20952254
J Clin Oncol. 2011 May 1;29(13):1785-94
pubmed: 21220591
J Low Genit Tract Dis. 2015 Oct;19(4):e60-3
pubmed: 26360235
Gynecol Oncol Rep. 2015 Apr 11;13:23-5
pubmed: 26425714
Mod Pathol. 2016 Jan;29 Suppl 1:S12-28
pubmed: 26715171
Oncotarget. 2016 Oct 4;7(40):64665-64673
pubmed: 27572321
NPJ Genom Med. 2016 Mar 16;1:16004
pubmed: 29263809
J Clin Oncol. 1998 Aug;16(8):2613-9
pubmed: 9704710

Auteurs

Alexandra Arfi (A)

Department of Surgery, Institut Curie, 92210, St Cloud, France.

Delphine Hequet (D)

Department of Surgery, Institut Curie, 92210, St Cloud, France.
Institut Curie, Inserm U900 - Bioinformatics, biostatistics, epidemiology and computational systems. Cancer biology, 35, rue Dailly, 92210, Saint-Cloud, France.

Guillaume Bataillon (G)

Department of Pathology, Institut Curie, 75005, Paris, France.

Carine Tran-Perennou (C)

Department of Pathology, Institut Curie, 75005, Paris, France.

Fereshteh Farkhondeh (F)

Department of Pathology, Institut Curie, 75005, Paris, France.

Xavier Sastre-Garau (X)

Department of Pathology, Institut de Cancérologie de Lorraine, 54519, Vandoeuvre-Lès-Nancy, France.

Virginie Fourchotte (V)

Department of Surgery, Institut Curie, 92210, St Cloud, France.

Roman Rouzier (R)

Department of Surgery, Institut Curie, 92210, St Cloud, France.
Institut Curie, Inserm U900 - Bioinformatics, biostatistics, epidemiology and computational systems. Cancer biology, 35, rue Dailly, 92210, Saint-Cloud, France.

Enora Laas (E)

Department of Surgery, Institut Curie, 92210, St Cloud, France.

Nicolas Pouget (N)

Department of Surgery, Institut Curie, 92210, St Cloud, France.

Anne Vincent-Salomon (A)

Department of Pathology, Institut Curie, 75005, Paris, France.

Emmanuelle Jeannot (E)

Department of Pathology, Institut Curie, 75005, Paris, France. emmanuelle.jeannot@curie.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH